# Managed Access Program of Venglustat in Pediatric and Adult Patients With Type 3 Gaucher Disease (GD3).

> **NCT07675031** · — · AVAILABLE · sponsor: **Sanofi**

## Conditions studied

- Type 3 Gaucher Disease

## Interventions

- **DRUG:** GZ402671

## Key facts

- **NCT ID:** NCT07675031
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07675031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07675031, "Managed Access Program of Venglustat in Pediatric and Adult Patients With Type 3 Gaucher Disease (GD3).". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07675031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*